# Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions

> **NCT00834067** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
- **DRUG:** UNIRETIC® 15/25 mg tablets

## Key facts

- **NCT ID:** NCT00834067
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2003-11
- **Final completion:** 2003-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00834067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00834067, "Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00834067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*